Primary Site >> Pancreatic Cancer
Gene >> THBS1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: The effect of thrombospondin-1 and TGF-beta 1 on pancreatic cancer cell invasion. PMID: 9695745 |
Ref: Thrombospondin-1 and transforming growth factor beta-1 upregulate plasminogen activator inhibitor type 1 in pancreatic cancer. PMID: 10482694 |
Ref: Hypermethylation of multiple genes in pancreatic adenocarcinoma. PMID: 10766168 Ref: Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. PMID: 10944227 |
Ref: Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel density. PMID: 11253112 Ref: The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer. PMID: 11332689 Ref: Expression of thrombospondin-1 in human pancreatic adenocarcinomas: role in matrix metalloproteinase-9 production. PMID: 11882904 |
Ref: Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma. PMID: 12429967 Ref: Pancreatic tumor growth is regulated by the balance between positive and negative modulators of angiogenesis. PMID: 12831059 |
Ref: Antiangiogenic treatment with the three thrombospondin-1 type 1 repeats recombinant protein in an orthotopic human pancreatic cancer model. PMID: 15788685 Ref: Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. PMID: 16046552 Ref: Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model. PMID: 16061881 |
Ref: Continuous administration of the three thrombospondin-1 type 1 repeats recombinant protein improves the potency of therapy in an orthotopic human pancreatic cancer model. PMID: 16757110 Ref: Adeno-associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin. PMID: 17606731 Ref: [Relationship between changes of serum concentrations of antiangiogenic factors and disease progression in patients of pancreatic carcinoma]. PMID: 18067717 |
Ref: Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model. PMID: 18347150 Ref: Thrombospondin-2 inhibits tumor cell invasion through the modulation of MMP-9 and uPA in pancreatic cancer cells. PMID: 21479427 |
Ref: Methylation profile of circulating plasma DNA in patients with pancreatic cancer. PMID: 19065635 Ref: Upregulation of thrombospondin-1 and angiogenesis in an aggressive human pancreatic cancer cell line selected for high metastasis. PMID: 19584238 Ref: Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer. PMID: 19805200 |
Ref: Netrin-1 mediates early events in pancreatic adenocarcinoma progression, acting on tumor and endothelial cells. PMID: 20080097 Ref: A combinatorial approach for targeted delivery using small molecules and reversible masking to bypass nonspecific uptake in vivo. PMID: 20463761 Ref: MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms. PMID: 21037952 |
Ref: Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. PMID: 21390185 Ref: Myelosuppression of thrombocytes and monocytes is associated with a lack of synergy between chemotherapy and anti-VEGF treatment. PMID: 21532882 Ref: Counterbalancing angiogenic regulatory factors control the rate of cancer progression and survival in a stage-specific manner. PMID: 21622854 Ref: Platelet-stored angiogenesis factors: clinical monitoring is prone to artifacts. PMID: 21896999 |
Ref: Knockdown of radixin by RNA interference suppresses the growth of human pancreatic cancer cells in vitro and in vivo. PMID: 22631643 Ref: Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1. PMID: 23019415 Ref: S100A4 siRNA inhibits human pancreatic cancer cell invasion in vitro. PMID: 23026527 |
Ref: Response of human pancreatic cancer cell xenografts to tetraiodothyroacetic acid nanoparticles. PMID: 23456390 Ref: Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells. PMID: 23649709 |
Ref: Glycoprotein biomarker panel for pancreatic cancer discovered by quantitative proteomics analysis. PMID: 24571389 Ref: Quantitative analysis of single amino acid variant peptides associated with pancreatic cancer in serum by an isobaric labeling quantitative method. PMID: 25393578 |
Ref: Identification of TAX2 peptide as a new unpredicted anti-cancer agent. PMID: 26046793 |
Ref: Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus. PMID: 26573598 Ref: Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness. PMID: 27701147 |
Ref: Thrombospondin-targeting TAX2 peptide impairs tumor growth in preclinical mouse models of childhood neuroblastoma. PMID: 27842053 Ref: A combination of platelet features allows detection of early-stage cancer. PMID: 28527393 |
Ref: Construction of a prognostic prediction system for pancreatic ductal adenocarcinoma to investigate the key prognostic genes. PMID: 29115420 |